Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Other financing activities (2020 - 2022)

Ovid Therapeutics' Other financing activities history spans 3 years, with the latest figure at -$56943.0 for Q4 2022.

  • For Q4 2022, Other financing activities fell 71.11% year-over-year to -$56943.0; the TTM value through Sep 2022 reached $23665.0, down 59.44%, while the annual FY2021 figure was $21314.0, 239.89% up from the prior year.
  • Other financing activities reached -$56943.0 in Q4 2022 per OVID's latest filing, down from $56943.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $81692.0 in Q3 2021 to a low of -$56943.0 in Q4 2022.
  • Average Other financing activities over 3 years is $607.8, with a median of -$2422.5 recorded in 2020.
  • The largest YoY upside for Other financing activities was 15228.15% in 2021 against a maximum downside of 987.41% in 2021.
  • A 3-year view of Other financing activities shows it stood at $3750.0 in 2020, then tumbled by 987.41% to -$33278.0 in 2021, then tumbled by 71.11% to -$56943.0 in 2022.
  • Per Business Quant, the three most recent readings for OVID's Other financing activities are -$56943.0 (Q4 2022), $56943.0 (Q3 2022), and $4305.0 (Q2 2022).